Inclusion Criteria:

- 20 years and older

- Histologically or cytologically confirmed Lymphoma that have failed to standard
therapy or for which no life prolonging treatment exists

- ECOG PS 0-2

- Life expectancy 12 weeks

- Hematopoietic: ANC ≥ 1,500/mm3, Platelet ≥ 100,000/mm3, Hemoglobin ≥ 9.0g/dL,
Prothrombin time, Activated partial thromboplastin time: normal range

- Hepatic: total bilirubin ≤ 1.5×ULN(except Gilbert's syndrome patients), AST, ALT ≤
3.0×ULN(AST, ALT ≤ 5.0×ULN in case of liver metastases)

- Renal: serum creatinine ≤ 1.5×ULN

- Signed a written informed consent

Exclusion Criteria:

- Have symptoms with Brain metastases

- History of Ischemic heart disease(e.g., myocardial infarction, unstable angina
pectoris) or Clinically significant heart disease such as NYHA Class III and IV
Congestive atrial arrhythmias, within 6 months prior to first dose of study drug

- Acute infection or blooding tendencies that would preclude study compliance

- Other psychiatric disorders or other conditions that would preclude study compliance

- Receiving antitumor therapy(surgery, immunotherapy or chemotherapy) within 4 weeks
prior to first dose of study drug(6 weeks for nitrosoureas and mitomycin C, 2 weeks
for radiation therapy)

- Other concurrent antitumor therapy

- Have Cardiac disease by nature

- History of HDAC agent

- History of Serious hypersensitivity or allergy

- Pregnant or nursing, active serum pregnancy test. Fertile patients must use effective
contraception

- Participation in a clinical trial within 4 weeks of first dose of study drug